These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36359404)

  • 1. Adenovirus-Inspired Virus-Like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses.
    Besson S; Laurin D; Chauvière C; Thépaut M; Kleman JP; Pezet M; Manches O; Fieschi F; Aspord C; Fender P
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth.
    Besson S; Boucher E; Laurin D; Manches O; Aspord C; Hannani D; Fender P
    Mol Ther Methods Clin Dev; 2023 Mar; 28():76-89. PubMed ID: 36620074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients.
    Sosa Cuevas E; Valladeau-Guilemond J; Mouret S; Roubinet B; de Fraipont F; Landemarre L; Charles J; Bendriss-Vermare N; Chaperot L; Aspord C
    Front Immunol; 2022; 13():1040600. PubMed ID: 36353633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BDCA1
    Sosa Cuevas E; Ouaguia L; Mouret S; Charles J; De Fraipont F; Manches O; Valladeau-Guilemond J; Bendriss-Vermare N; Chaperot L; Aspord C
    Clin Transl Immunology; 2020; 9(11):e1190. PubMed ID: 33282290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The melanoma tumor glyco-code impacts human dendritic cells' functionality and dictates clinical outcomes.
    Sosa Cuevas E; Roubinet B; Mouret S; Thépaut M; de Fraipont F; Charles J; Fieschi F; Landemarre L; Chaperot L; Aspord C
    Front Immunol; 2023; 14():1120434. PubMed ID: 36891308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
    Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
    Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs.
    Ouaguia L; Dufeu-Duchesne T; Leroy V; Decaens T; Reiser JB; Sosa Cuevas E; Durantel D; Valladeau-Guilemond J; Bendriss-Vermare N; Chaperot L; Aspord C
    Clin Transl Immunology; 2020; 9(12):e1208. PubMed ID: 33312564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform.
    Chevillard C; Amen A; Besson S; Hannani D; Bally I; Dettling V; Gout E; Moreau CJ; Buisson M; Gallet S; Fenel D; Vassal-Stermann E; Schoehn G; Poignard P; Dagher MC; Fender P
    Mol Ther; 2022 May; 30(5):1913-1925. PubMed ID: 35151843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
    Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
    Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
    Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
    Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses.
    Alam MM; Jarvis CM; Hincapie R; McKay CS; Schimer J; Sanhueza CA; Xu K; Diehl RC; Finn MG; Kiessling LL
    ACS Nano; 2021 Jan; 15(1):309-321. PubMed ID: 32790346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
    Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
    J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.
    Naveh HP; Vujanovic L; Butterfield LH
    J Immunother Cancer; 2013; 1():19. PubMed ID: 24829755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.
    Fotaki G; Jin C; Kerzeli IK; Ramachandran M; Martikainen MM; Karlsson-Parra A; Yu D; Essand M
    Oncoimmunology; 2018; 7(3):e1397250. PubMed ID: 29399398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell biology and its role in tumor immunotherapy.
    Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
    J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Dendritic Cell Activation by Virus-Based Vaccine Delivery Vectors Emphasizes the Transcriptional Downregulation of the Oxidative Phosphorylation Pathway.
    Tsitoura E; Kazazi D; Oz-Arslan D; Sever EA; Khalili S; Vassilaki N; Aslanoglou E; Dérian N; Six A; Sezerman OU; Klatzmann D; Mavromara P
    Hum Gene Ther; 2019 Apr; 30(4):429-445. PubMed ID: 30351174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
    Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
    Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.